Item 4.01.Changes in Registrant's Certifying Accountant.
As previously disclosed, on August 1, 2023, PharmaCyte Biotech, Inc. (the "Company") was informed by Armanino LLP ("Armanino"), the Company's then current independent registered public accounting firm, that Armanino would resign as the Company's independent auditor (not related to any actions taken by the Company). Armanino advised the Company that its decision to resign was due solely to Armanino's decision to exit from the practice of providing financial statement audit services to all its public company engagements.
On November 5, 2023, the Company engaged Marcum LLP ("Marcum") as its new independent registered public accounting firm.
During the two fiscal years ended December 31, 2021 and 2022, and the subsequent interim period through November 5, 2023, the Company has not consulted with Marcum regarding either: (i) the application of accounting principles to any specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's financial statements; or (ii) any matter that was either the subject of a disagreement (as defined in Regulation S-K, Item 304(a)(1)(iv) and the related instructions) or reportable event (as defined in Regulation S-K, Item 304(a)(1)(v)).